{"id":3081,"date":"2025-12-25T04:15:17","date_gmt":"2025-12-25T04:15:17","guid":{"rendered":"https:\/\/bukka.phar.kyushu-u.ac.jp\/?post_type=publication&#038;p=3081"},"modified":"2026-02-25T04:16:00","modified_gmt":"2026-02-25T04:16:00","slug":"deferiprone-therapy-improves-the-oxidative-status-of-ldl-in-patients-with-%ce%b2-thalassaemia-hbe","status":"publish","type":"publication","link":"https:\/\/bukka.phar.kyushu-u.ac.jp\/en\/publication\/deferiprone-therapy-improves-the-oxidative-status-of-ldl-in-patients-with-%ce%b2-thalassaemia-hbe\/","title":{"rendered":"Deferiprone therapy improves the oxidative status of LDL in patients with \u03b2-thalassaemia\/HbE"},"content":{"rendered":"<div class=\"publication_wrap\">\n\t<h3><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41384052\/\" target=\"_blank\">Deferiprone therapy improves the oxidative status of LDL in patients with \u03b2-thalassaemia\/HbE<\/a><\/h3>\n\t\n  Tran NT, Lerksaipheng P, Sutcharitchan P, Rojnuckarin P, Yamada KI, Morales NP,  Luechapudiporn R<br>\n  <em>Drugs Context.<\/em>\n  2:14:2025-7-6, 2025<\/div>","protected":false},"featured_media":0,"template":"","_links":{"self":[{"href":"https:\/\/bukka.phar.kyushu-u.ac.jp\/wp-json\/wp\/v2\/publication\/3081"}],"collection":[{"href":"https:\/\/bukka.phar.kyushu-u.ac.jp\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/bukka.phar.kyushu-u.ac.jp\/wp-json\/wp\/v2\/types\/publication"}],"version-history":[{"count":1,"href":"https:\/\/bukka.phar.kyushu-u.ac.jp\/wp-json\/wp\/v2\/publication\/3081\/revisions"}],"predecessor-version":[{"id":3082,"href":"https:\/\/bukka.phar.kyushu-u.ac.jp\/wp-json\/wp\/v2\/publication\/3081\/revisions\/3082"}],"wp:attachment":[{"href":"https:\/\/bukka.phar.kyushu-u.ac.jp\/wp-json\/wp\/v2\/media?parent=3081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}